DGIdb - LINSITINIB Drug Record

LINSITINIB chembl:CHEMBL1091644 Antineoplastic

Alternate Names:

ASP-7487
OSI-906AA
LINSITINIB
OSI-906

Drug Info:

Pharmaceutical Developer	OSI Pharmaceuticals
Source Reported Drug Name(s)	OSI-906
Drug Class	IGF1R Inhibitor
FDA Approval	not approved
Drug Class	small molecule
Drug Indications	antineoplastic agent
Drug Class	Kinase Inhibitors
Drug Type	small molecule
Drug Groups	investigational

(8 More Sources)

Publications:

de Lint et al., 2016, Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R., Mol. Cancer Ther.
Ma et al., 2016, InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma., Clin. Cancer Res.
Vidal et al., 2015, A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer., Cancer Cell
Hayes et al., 2016, Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression., Cancer Cell

LINSITINIB INSRR

Interaction Score: 2.37

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
GuideToPharmacology
LINSITINIB IGF1R

Interaction Score: 1.52

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name OSI-906

Novel drug target Established target

Notes

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial CancerCommons TdgClinicalTrial TTD DrugBank TALC MyCancerGenome GuideToPharmacology ChemblInteractions
LINSITINIB IGF2

Interaction Score: 1.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25670080

Sources:
CIViC
LINSITINIB INSR

Interaction Score: 0.32

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
TALC GuideToPharmacology ChemblInteractions
LINSITINIB PTEN

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Gefitinib + Linsitinib

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
26561558

Sources:
JAX-CKB
LINSITINIB KRAS

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Linsitinib + SCH772984

Indication/Tumor Type pancreatic ductal adenocarcinoma

Response Type sensitive

PMIDs:
26725216

Sources:
JAX-CKB
LINSITINIB PIK3CA

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy GDC-0941 + Linsitinib

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

PMIDs:
27196766

Sources:
JAX-CKB
LINSITINIB EGFR

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Gefitinib + Linsitinib

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
26561558

Sources:
JAX-CKB

MyCancerGenome: LINSITINIB
- Version: 20-Jun-2017
Alternate Names:

OSI-906 Development Name

LINSITINIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
CancerCommons: LINSITINIB
- Version: 25-July-2013
Alternate Names:

3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol PubChem Drug Name

11640390 PubChem Drug ID

OSI-906 Drug Trade Name

Drug Info:

Drug Class IGF1R Inhibitor

Source Reported Drug Name(s) OSI-906

Pharmaceutical Developer OSI Pharmaceuticals

Publications:
DrugBank: DB06075
- Version: 5.1.7
Alternate Names:

LINSITINIB DrugBank Drug Name

867160-71-2 CAS Number

CHEMBL1091644 ChEMBL ID

Drug Info:

Drug Type small molecule

Drug Groups investigational

Publications:
TdgClinicalTrial: OSI-906
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class small molecule

FDA Approval not approved

Publications:

JAX-CKB: Linsitinib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

de Lint et al., 2016, Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R., Mol. Cancer Ther.

Hayes et al., 2016, Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression., Cancer Cell

Ma et al., 2016, InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma., Clin. Cancer Res.

CIViC: LINSITINIB
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

Vidal et al., 2015, A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer., Cancer Cell
TTD: OSI-906
- Version: 2020.06.01
Alternate Names:

D01GFX TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178103995
- Version: 29-September-2020
Alternate Names:

LINSITINIB GuideToPharmacology Ligand Name

Drug Info:

Publications:
TALC: LINSITINIB
- Version: 12-May-2016
Alternate Names:

LINSITINIB Primary Drug Name

LINSITINIB Drug Generic Name

OSI-906 Drug Synonym

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1091644
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1091644
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: LINSITINIB
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:

Direct Interaction?	False
Endogenous Drug?	False
Specific Action of the Ligand	Inhibition

combination therapy	Gefitinib + Linsitinib
Indication/Tumor Type	glioblastoma multiforme
Response Type	sensitive

combination therapy	Linsitinib + SCH772984
Indication/Tumor Type	pancreatic ductal adenocarcinoma
Response Type	sensitive

combination therapy	GDC-0941 + Linsitinib
Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	sensitive

3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol	PubChem Drug Name
11640390	PubChem Drug ID
OSI-906	Drug Trade Name

LINSITINIB	DrugBank Drug Name
867160-71-2	CAS Number
CHEMBL1091644	ChEMBL ID

LINSITINIB	Primary Drug Name
LINSITINIB	Drug Generic Name
OSI-906	Drug Synonym

Trial Name	OSI-906
Novel drug target	Established target
Notes

LINSITINIB Drug Record

LINSITINIB chembl:CHEMBL1091644 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: None found

Sources: GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name OSI-906 Novel drug target Established target Notes

PMIDs: None found

Sources: ClearityFoundationClinicalTrial CancerCommons TdgClinicalTrial TTD DrugBank TALC MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25670080

Sources: CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: None found

Sources: TALC GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Gefitinib + Linsitinib Indication/Tumor Type glioblastoma multiforme Response Type sensitive

PMIDs: 26561558

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Linsitinib + SCH772984 Indication/Tumor Type pancreatic ductal adenocarcinoma Response Type sensitive

PMIDs: 26725216

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy GDC-0941 + Linsitinib Indication/Tumor Type triple-receptor negative breast cancer Response Type sensitive

PMIDs: 27196766

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Gefitinib + Linsitinib Indication/Tumor Type glioblastoma multiforme Response Type sensitive

PMIDs: 26561558

Sources: JAX-CKB

MyCancerGenome: LINSITINIB

Alternate Names: OSI-906 Development Name LINSITINIB Generic Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

CancerCommons: LINSITINIB

Alternate Names: 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol PubChem Drug Name 11640390 PubChem Drug ID OSI-906 Drug Trade Name

Drug Info: Drug Class IGF1R Inhibitor Source Reported Drug Name(s) OSI-906 Pharmaceutical Developer OSI Pharmaceuticals

Publications:

DrugBank: DB06075

Alternate Names: LINSITINIB DrugBank Drug Name 867160-71-2 CAS Number CHEMBL1091644 ChEMBL ID

Drug Info: Drug Type small molecule Drug Groups investigational

Publications:

TdgClinicalTrial: OSI-906

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class small molecule FDA Approval not approved

Publications:

JAX-CKB: Linsitinib

Alternate Names:

Drug Info:

CIViC: LINSITINIB

Alternate Names:

Drug Info:

Publications: Vidal et al., 2015, A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer., Cancer Cell

TTD: OSI-906

Alternate Names: D01GFX TTD Drug ID

Drug Info:

Publications:

GuideToPharmacology: 178103995

Alternate Names: LINSITINIB GuideToPharmacology Ligand Name

Drug Info:

Publications:

TALC: LINSITINIB

Alternate Names: LINSITINIB Primary Drug Name LINSITINIB Drug Generic Name OSI-906 Drug Synonym

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1091644

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1091644

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name OSI-906

Novel drug target Established target

Notes

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial CancerCommons TdgClinicalTrial TTD DrugBank TALC MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
25670080

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
TALC GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Gefitinib + Linsitinib

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
26561558

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Linsitinib + SCH772984

Indication/Tumor Type pancreatic ductal adenocarcinoma

Response Type sensitive

PMIDs:
26725216

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy GDC-0941 + Linsitinib

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

PMIDs:
27196766

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Gefitinib + Linsitinib

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
26561558

Sources:
JAX-CKB

Alternate Names:

OSI-906 Development Name

LINSITINIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Alternate Names:

3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol PubChem Drug Name

11640390 PubChem Drug ID

OSI-906 Drug Trade Name

Drug Info:

Drug Class IGF1R Inhibitor

Source Reported Drug Name(s) OSI-906

Pharmaceutical Developer OSI Pharmaceuticals

Alternate Names:

LINSITINIB DrugBank Drug Name

867160-71-2 CAS Number

CHEMBL1091644 ChEMBL ID

Drug Info:

Drug Type small molecule

Drug Groups investigational

Drug Info:

Drug Indications antineoplastic agent

Drug Class small molecule

FDA Approval not approved

Publications:

Vidal et al., 2015, A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer., Cancer Cell

Alternate Names:

D01GFX TTD Drug ID

Alternate Names:

LINSITINIB GuideToPharmacology Ligand Name

Alternate Names:

LINSITINIB Primary Drug Name

LINSITINIB Drug Generic Name

OSI-906 Drug Synonym